Gout: An overview of available urate lowering therapies;Les traitements hypo-uricémiants disponibles dans la goutte

Annales Pharmaceutiques Francaises

Volumn 70, Issue 3, 2012, Pages 133-138

  Richette, P ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Allopurinol; Febuxostat; Gout; Treatments; Urate lowering therapies; Uricase

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; PEGLOTICASE; URATE; URATE OXIDASE; URIC ACID; XANTHINE OXIDASE;

ARTHROPATHY; GOUT; HUMAN; HYPERURICEMIA; KIDNEY FAILURE; SHORT SURVEY;

ALLOPURINOL; ENZYME INHIBITORS; GOUT; GOUT SUPPRESSANTS; GUIDELINES AS TOPIC; HUMANS; ORGAN TRANSPLANTATION; POLYETHYLENE GLYCOLS; THIAZOLES; URATE OXIDASE; URIC ACID; URICOSURIC AGENTS; XANTHINE OXIDASE;

EID: 84861707703     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2012.02.003     Document Type: Short Survey

References (33)

1. Zhang W., Doherty M., Bardin T., Pascual E., Barskova V., Conaghan P., et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65(10):1312-1324.
2. Jordan K.M., Cameron J.S., Snaith M., Zhang W., Doherty M., Seckl J., et al. British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007, 46(8):1372-1374.
3. Perez-Ruiz F., Calabozo M., Pijoan J.I., Herrero-Beites A.M., Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47(4):356-360.
4. Ferraz M.B., O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995, 22(5):908-914.
5. Campion E.W., Glynn R.J., DeLabry L.O. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987, 82(3):421-426.
6. van Lieshout-Zuidema M.F., Breedveld F.C. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993, 20(8):1383-1385.
7. Borstad G.C., Bryant L.R., Abel M.P., Scroggie D.A., Harris M.D., Alloway J.A. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004, 31(12):2429-2432.
8. Sarawate C.A., Brewer K.K., Yang W., Patel P.A., Schumacher H.R., Saag K.G., et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006, 81(7):925-934.
9. Reinders M.K., Haagsma C., Jansen T.L., van Roon E.N., Delsing J., van de Laar M.A., et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600mg/day versus benzbromarone 100-200mg/day in patients with gout. Ann Rheum Dis 2009, 68(6):892-897.
10. Chao J., Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009, 11(2):135-140.
11. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010, 6(1):30-38.
12. Hande K.R., Noone R.M., Stone W.J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76(1):47-56.
13. Stamp L.K., O'Donnell J.L., Zhang M., James J., Frampton C., Barclay M.L., et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011, 63(2):412-421.
14. Picard D., Janela B., Descamps V., D'Incan M., Courville P., Jacquot S., et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2011, 2(46):ra62.
15. Schumacher H.R., Becker M.A., Wortmann R.L., Macdonald P.A., Hunt B., Streit J., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008, 59(11):1540-1548.
16. Becker M.A., Schumacher H.R., Wortmann R.L., MacDonald P.A., Eustace D., Palo W.A., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353(23):2450-2461.
17. Jansen T.L., Richette P., Perez-Ruiz F., Tausche A.K., Guerne P.A., Punzi L., et al. International position paper on febuxostat. Clin Rheumatol 2010, 29(8):835-840.
18. Becker M.A., Schumacher H.R., Espinoza L.R., Wells A.F., MacDonald P., Lloyd E., et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010, 12(2):R63.
19. Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004, 71(6):481-485.
20. Hamada T., Ichida K., Hosoyamada M., Mizuta E., Yanagihara K., Sonoyama K., et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008, 21(10):1157-1162.
21. Uetake D., Ohno I., Ichida K., Yamaguchi Y., Saikawa H., Endou H., et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med 2010, 49(2):89-94.
22. Wu X.W., Muzny D.M., Lee C.C., Caskey C.T. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992, 34(1):78-84.
23. Richette P., Bardin T. Gout. Lancet 2010, 375(9711):318-328.
24. Richette P., Briere C., Hoenen-Clavert V., Loeuille D., Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007, 34(10):2093-2098.
25. Terkeltaub R. Learning how and when to employ uricase as bridge therapy in refractory gout. J Rheumatol 2007, 34(10):1955-1958.
26. Burns C.M., Wortmann R.L. Gout therapeutics: new drugs for an old disease. Lancet 2011, 377(9760):165-177.
27. Sherman M.R., Saifer M.G., Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008, 60(1):59-68.
28. Sundy J.S., Ganson N.J., Kelly S.J., Scarlett E.L., Rehrig C.D., Huang W., et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56(3):1021-1028.
29. Sundy J.S. Gout management: let's get it right this time. Arthritis Rheum 2008, 59(11):1535-1537.
30. Sundy J.S., Becker M.A., Baraf H.S., Barkhuizen A., Moreland L.W., Huang W., et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum 2008, 58(9):2882-2891.
31. Anderson A., Singh J.A. Pegloticase for chronic gout. Cochrane Database Syst Rev 2010, 3:CD008335.
32. Baraf H.S., Matsumoto A.K., Maroli A.N., Waltrip R.W. Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum 2008, 58(11):3632-3634.
33. Sundy J.S., Baraf H.S., Yood R.A., Edwards N.L., Gutierrez-Urena S.R., Treadwell E.L., et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011, 306(7):711-720.